Intepirdine
{{Short description|Chemical compound}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 451551710
| IUPAC_name = 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline
| image = Intepirdine.svg
| tradename =
| legal_status = Investigational/abandoned
| routes_of_administration = Oral
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 607742-69-8
| ATC_prefix = none
| PubChem = 11256720
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1083390
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2IOB2M82HY
| KEGG = D10942
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 9431746
| synonyms = SB-742457, RVT-101
| C=19 | H=19 | N=3 | O=2 | S=1
| smiles = C3CNCCN3c1cccc(c1nc4)cc4S(=O)(=O)c2ccccc2
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = JJZFWROHYSMCMU-UHFFFAOYSA-N
}}
Intepirdine (INN; developmental codes SB-742457, RVT-101){{cite web|title=Intepirdine - Axovant Sciences / GlaxoSmithKline|url=http://adisinsight.springer.com/drugs/800020107|publisher=AdisInsight|access-date=9 January 2018|language=en}} is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects.{{cite journal |vauthors=Upton N, Chuang TT, Hunter AJ, Virley DJ | title = 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease | journal = Neurotherapeutics | volume = 5 | issue = 3 | pages = 458–69 |date=July 2008 | pmid = 18625457 | doi = 10.1016/j.nurt.2008.05.008| pmc = 5084247 }}{{cite journal |vauthors=Rossé G, Schaffhauser H | title = 5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment | journal = Current Topics in Medicinal Chemistry | volume = 10| issue = 2| pages = 207–21|date=February 2010 | pmid = 20166958 | doi = 10.2174/156802610790411036}} It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.{{cite news|last1=Lowe|first1=Derek|title=An Alzheimer's IPO, Because Why Not|url=https://www.science.org/content/blog-post/alzheimer-s-ipo-because-why-not|work=In the Pipeline|date=12 May 2015}}
Results of a phase III clinical trial for the treatment of Alzheimer's disease were reported in September 2017.{{cite news|last1=Fiore|first1=Kristina|title=NeuroBreak: Alzheimer's Drug Bombs; Elephant Tranquilizer ODs|url=https://www.medpagetoday.com/Neurology/GeneralNeurology/60482|work=MedPage Today|date=27 September 2016|language=en}} The trial showed no improvement over control group and Axovant lost 70% of its value upon the announcement of the trial results.{{cite news|last1=Garde|first1=Damian|title=Another Alzheimer's failure: Axovant's drug flops in late-stage trial|url=https://www.statnews.com/2017/09/26/axovant-intepirdine-trial/|work=STAT|date=26 September 2017}}
Intepirdine also entered clinical trials for dementia with Lewy bodies, also with negative results.{{cite news | url = https://www.fiercebiotech.com/biotech/axovant-slumps-as-it-dumps-lead-drug-intepirdine | title = Axovant slumps as it dumps lead drug intepirdine | publisher = Fierce Biotech | date = Jan 8, 2018|last=Taylor|first=Phil}} Consequently, Axovant announced in 2018 that it has discontinued development of this drug.